This includes analysis of Adalimumab, Infliximab and Etanercept (TNF inhibitors) in psoriatic arthritis [97], Ixekizumab (IL-17A monoclonal antibody) in moderate-to-severe psoriasis [98], Secukinumab (IL-17A monoclonal antibody) in moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis [99,100], Canakinumab (IL-1β monoclonal antibody) in systemic JIA [101], Sarilumab (IL-6 receptor) in rheumatoid arthritis [102] and Tildrakizumab (IL23 monoclonal antibody) in moderate-to-severe psoriasis [103]. Here, IL17A is linked to psoriasis vulgaris.